Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging
Denise P. Muñoz, Steven M. Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam M. Freund, Francis Rodier, Jennifer D. Wu, Pierre-Yves Desprez, David H. Raulet, Peter S. Nelson, Laura J. van ’t Veer, Judith Campisi, Jean-Philippe Coppé
Denise P. Muñoz, Steven M. Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam M. Freund, Francis Rodier, Jennifer D. Wu, Pierre-Yves Desprez, David H. Raulet, Peter S. Nelson, Laura J. van ’t Veer, Judith Campisi, Jean-Philippe Coppé
View: Text | PDF
Research Article Aging Oncology

Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging

  • Text
  • PDF
Abstract

Cellular senescence is a tumor-suppressive mechanism that can paradoxically contribute to aging pathologies. Despite evidence of immune clearance in mouse models, it is not known how senescent cells (SnCs) persist and accumulate with age or in tumors in individuals. Here, we identify cooperative mechanisms that orchestrate the immunoevasion and persistence of normal and cancer human SnCs through extracellular targeting of natural killer receptor signaling. Damaged SnCs avoided immune recognition through MMP-dependent shedding of NKG2D ligands reinforced via paracrine suppression of NKG2D receptor–mediated immunosurveillance. These coordinated immunoediting processes were evident in residual, drug-resistant tumors from cohorts of more than 700 prostate and breast cancer patients treated with senescence-inducing genotoxic chemotherapies. Unlike in mice, these reversible senescence subversion mechanisms were independent of p53/p16 and exacerbated in oncogenic RAS-induced senescence. Critically, the p16INK4A tumor suppressor could disengage the senescence growth arrest from the damage-associated immune senescence program, which was manifest in benign nevus lesions, where indolent SnCs accumulated over time and preserved a non-proinflammatory tissue microenvironment maintaining NKG2D-mediated immunosurveillance. Our study shows how subpopulations of SnCs elude immunosurveillance and reveals potential secretome-targeted therapeutic strategies to selectively eliminate — and restore the clearance of — the detrimental SnCs that actively persist after chemotherapy and accumulate at sites of aging pathologies.

Authors

Denise P. Muñoz, Steven M. Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam M. Freund, Francis Rodier, Jennifer D. Wu, Pierre-Yves Desprez, David H. Raulet, Peter S. Nelson, Laura J. van ’t Veer, Judith Campisi, Jean-Philippe Coppé

×

Figure 2

p53/p16-independent upregulation of NKG2D ligands in damaged SnCs, but not in CDKI-induced SnCs.

Options: View larger image (or click on image) Download as PowerPoint
p53/p16-independent upregulation of NKG2D ligands in damaged SnCs, but n...
(A, C, E, and G) NKG2D ligand mRNA levels measured by quantitative real-time PCR in fibroblasts. For each gene transcript (MICA/B, ULBP-1, -2, -3), fold changes were first normalized to the average expression levels across PRE cells, and then values averaged across cell types for each condition. The number of individual samples (n) tested at least in quadruplicate by TaqMan assay is indicated. Profiles are subdivided into 4 blocks: (A) p53/p16 WT XRA or REP senescence. CON, control empty lentiviral vector. (C) p53/p16-deficient XRA or REP senescence, where the sequence of interventions is annotated as follows: p53/p16-induced deficiency followed by XRA/REP-induced senescence — SEN (p53–/p16– XRA/REP) (i.e., loss of p53 or p16 before senescence); XRA/REP-induced senescence followed by p53-induced deficiency — SEN (XRA/REP → p53–) (i.e., loss of p53 after senescence). (E) Transient DDR and ATM-deficient senescence, annotated as 0.5 Gy and ATM–. (G) p16/p21-induced senescence growth arrest, annotated as +p16 or +p21. (B, D, F, and H) Cell surface presentation of NKG2D ligands. (B) Immunofluorescence of cell surface NKG2D ligands (using recombinant NKG2D receptor coupled to an Fc fragment (rNKG2D/Fc) to detect all NKG2D ligands [NKG2D-Ls]; top; green) or MICA (antibody against MICA; bottom; red), in PRE versus SEN (XRA) WI-38 cells. Original magnification, ×20. Box plots overlaid on bar graphs of averages show the signal intensity/cell quantification for PRE (n = 580) and XRA (n = 190) cells (box plot length: 25% and 75% of data; centerline: median; whiskers: 25% – (or 75% +) 1.5 × IQR; dots: outliers; color bars: average (Ave) ± SD; P value, 2-tailed Student’s t test. Immunofluorescence panels in D show cell surface NKG2D ligands in p53-deficient or p16-deficient XRA SnCs; (F) transiently damaged cells (10 days after low-dose [0.5 Gy] radiation); (H) p16-induced SnCs. Original magnification, ×20.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts